ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Catecholaminergic storm and extreme blood pressure lability induced by combined levodopa/benserazide, selegiline, and piribedil in Parkinson's disease: a case report.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular autonomic dysfunction was frequently observed in patients with Parkinson's disease (PD), and severe blood pressure (BP) fluctuations posing significant clinical challenges. Although current dopaminergic drugs, (e.g. levodopa/benserazide, selegiline, and piribedil) could improve motor symptoms, the underlying mechanisms of catecholamine storm triggered by concomitant use remained to be fully elucidated. CASE PRESENTATION: A 62-year-old female with PD was admitted in May 2025 due to abnormal BP fluctuations accompanied by fatigue lasting 20 days. In 2021, she was diagnosed with PD and received long-term treatment with levodopa/benserazide (125 mg tid), selegiline (2.5 mg tid), and piribedil (50 mg tid). Systolic blood pressure (SBP) measured in the hospital varied from 57 to 217 mmHg. A 24-hour peak urinary dopamine level of 36,733 µg/24 h was documented. Multidisciplinary consultation led to discontinuation of selegiline and piribedil while levodopa/benserazide was maintained. Within 72 h, her urinary dopamine levels decreased by 77% (to 8,424 µg/24 h), and standard deviation of BP was reduced from 29.59 to 9.95 mmHg-a 66% decrease. During 3-month follow-up period, the patient's home monitored SBP remained stable between 110 and 135 mmHg although her motor symptoms have advanced manifesting as ipsilateral limb tremors and increased muscle tone.
conclusionsThis case demonstrated that combined dopaminergic therapy could induce catecholamine storm via synergistic effects, leading to life-threatening fluctuations in BP. Timely identification and adjustment of treatment regimens could effectively reverse cardiovascular risk. However, it was crucial to carefully consider the balance between the progression of motor symptoms and changes in medication treatment.
Indexed as
Identifiers
41618077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.